Liver disease in dialysis patients.

[1]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[2]  J. Rosenblatt,et al.  Detection of hepatitis C viral sequences in non-A, non-B hepatitis , 1990, The Lancet.

[3]  D. Marcelli,et al.  Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. , 1996, Nephron.

[4]  A. Disney,et al.  Liver disease and the e antigen in HBsAg carriers with chronic renal failure. , 1980, Gut.

[5]  R. Charrel,et al.  Hepatitis GB virus C in patients on hemodialysis. , 1996, The New England journal of medicine.

[6]  A. Levey,et al.  Hepatitis C virus infection in dialysis and renal transplantation. , 1997, Kidney international.

[7]  A. Mitwalli.  Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. , 1996, Nephron.

[8]  S. Kashiwagi,et al.  Prevalence of antibody to hepatitis C virus in hemodialysis patients. , 1991, American journal of epidemiology.

[9]  W. Stremmel,et al.  Clinical impact of GB-C virus in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Ding‐Shinn Chen,et al.  Prevalence of anti‐HCV and HCV viremia in hemodialysis patients in Taiwan , 1992, Journal of medical virology.

[11]  M. Jadoul,et al.  Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. , 1998, Kidney international.

[12]  S. Kashiwagi,et al.  Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection , 2000, American Journal of Gastroenterology.

[13]  P. Rendo,et al.  A double‐blind controlled trial of recombinant interferon‐α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels , 1997 .

[14]  B. Rudensky,et al.  Vaccination against hepatitis B in children and adolescent patients on dialysis. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Y. Liaw,et al.  Prevalence of antibodies to hepatitis C virus in the hemodialysis unit. , 1991, American journal of nephrology.

[16]  C. Degott,et al.  Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. , 2008, Liver.

[17]  M. J. Cole,et al.  Biological dynamics of viral load in hemodialysis patients with hepatitis C virus , 2000 .

[18]  L. Stuyver,et al.  Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. , 1999, Artificial organs.

[19]  K. Deusch,et al.  The effect of granulocyte—macrophage colony‐stimulating factor (GM‐CSF) on hepatitis B vaccination in haemodialysis patients , 1996, Journal of viral hepatitis.

[20]  L. Friedman,et al.  Chronic viral hepatitis and the management of chronic renal failure. , 1995, Kidney international.

[21]  P. Simmonds,et al.  Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users , 1990, The Lancet.

[22]  H. Okamoto,et al.  Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non‐A‐G hepatitis , 1998, Journal of medical virology.

[23]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States, 1992. , 1994, ASAIO journal.

[24]  H. Salomón,et al.  Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine , 1994, The Lancet.

[25]  M. Alter,et al.  Hemodialysis‐Associated Hepatitis B: Revised Recommendations for Serologic Screening , 1990 .

[26]  B. Piraino,et al.  Low Seroconversion with Hepatitis B Vaccination in Peritoneal Dialysis Patients , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[27]  P. Parfrey,et al.  Chronic hepatitis in end-stage renal disease: comparison of HBsAg-negative and HBsAg-positive patients. , 1985, Kidney international.

[28]  P. Boyle,et al.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study , 1999, The Lancet.

[29]  J. Tsai,et al.  Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. , 1995, Nephron.

[30]  F. Bender.  Preventing Liver Disease in Peritoneal Dialysis Patients , 1995 .

[31]  N. Hayashi,et al.  Clinical implications of coinfection with a novel DNA virus (TTV) in hepatitis C virus carriers on maintenance hemodialysis , 1999, Journal of medical virology.

[32]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[33]  M. Alter,et al.  Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  S. Meuer,et al.  LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION , 1989, The Lancet.

[35]  A. Hatzakis,et al.  Hepatitis E virus (HEV) infection in haemodialysis patients , 1996 .

[36]  G. Danovitch,et al.  Histopathological features of hepatitis C in renal transplant candidates [see comment]. , 2000, Transplantation.

[37]  D. Marcelli,et al.  ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. , 1996, Kidney international.

[38]  Jules L. Dienstag,et al.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis , 1989 .

[39]  C. Verslype,et al.  High prevalence of hepatitis G virus infection compared with hepatitis C virus infection in patients undergoing chronic hemodialysis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  M. Alter,et al.  National Surveillance of Dialysis‐Associated Diseases in the United States, 1988 , 1990, ASAIO transactions.

[41]  F. Locatelli,et al.  Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  G. Walz,et al.  Factors influencing the response to hepatitis B vaccination of hemodialysis patients. , 1989, Nephron.

[43]  M. Haubitz,et al.  Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. , 1996, Clinical Nephrology.

[44]  R. Marcén,et al.  Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. , 1996, American journal of nephrology.

[45]  K. zum Büschenfelde,et al.  Active hepatitis B vaccination of dialysis patients and medical staff. , 1984, Kidney international.

[46]  F. Locatelli,et al.  GBV-C/HGV infection in end-stage renal disease: a serological and virological survey. , 2000, JN. Journal of Nephrology (Milano. 1992).

[47]  P. Jungers,et al.  Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. , 1984, Clinical nephrology.

[48]  P. Parfrey,et al.  The long-term outcome of hepatitis B infection in hemodialysis patients. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[50]  M. Mondelli,et al.  Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  S. Schalm,et al.  Immune response to hepatitis B vaccine in hemodialysis patients. , 1987, Nephron.

[52]  S. Emerson,et al.  High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease , 1999, Journal of medical virology.

[53]  F. Locatelli,et al.  Hepatitis E virus infection in haemodialysis patients: a seroepidemiological survey. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  K. Kamata,et al.  Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  E. Schiff,et al.  Hepatitis C infection in two urban hemodialysis units. , 1990, Kidney international.

[56]  F. Locatelli,et al.  Membrane Compatibility, Flux and HCV Infection in Dialysis Patients: Newer Evidence , 2000, The International journal of artificial organs.

[57]  R. Gish,et al.  The prevalence of hepatitis C virus antibodies among hemodialysis patients. , 1990, Annals of internal medicine.

[58]  S. Sandroni,et al.  Antibody to hepatitis C virus increases with time on hemodialysis. , 1992, Clinical nephrology.

[59]  M. Weir,et al.  Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  I. Hughes.  Care of the Child with Diabetes , 1987 .

[61]  M. Buti,et al.  Hepatitis E virus infection in acute hepatitis in Spain. , 1995, Journal of virological methods.

[62]  P. Van der Niepen,et al.  Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. , 1991, Kidney international.

[63]  F. Fabrizi,et al.  Hepatitis B Virus Infection in Dialysis Patients , 2000, American Journal of Nephrology.

[64]  F. Locatelli,et al.  Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[65]  F. Pizzarelli,et al.  Hepatitis B vaccination in dialysis patients and nutritional status. , 1992, Nephron.

[66]  J. Hamilton,et al.  Hepatitis B vaccines in patients with chronic renal failure before dialysis. , 1988, The Journal of infectious diseases.

[67]  M. Houghton,et al.  Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease , 1991, Hepatology.

[68]  J. Davis,et al.  Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. , 1988, American journal of epidemiology.

[69]  P. Gallian,et al.  TT Virus Infection in French Hemodialysis Patients: Study of Prevalence and Risk Factors , 1999, Journal of Clinical Microbiology.

[70]  T. Nishizawa,et al.  Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology , 1998 .

[71]  D. Marcelli,et al.  1983 to 1992: report on regular dialysis and transplantation in Lombardy. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[72]  T. Blackmore,et al.  Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy, and in the staff caring for them. , 1992, Australian and New Zealand journal of medicine.

[73]  F. Deinhardt,et al.  Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. , 1986, Journal of hepatology.

[74]  P. Simmonds,et al.  Detection of a novel DNA virus (TT virus) in blood donors and blood products , 1998, The Lancet.

[75]  F. Carnot,et al.  The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. , 1996, Transplantation.

[76]  M. Mizokami,et al.  TT virus infection among blood donors and patients with non-B, non-C liver diseases in Korea. , 1999, Journal of hepatology.

[77]  K. Reddy,et al.  Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  M. Mondelli,et al.  High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second generation assay. , 1992, Nephron.

[79]  S. Draibe,et al.  Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. , 1995, Nephrology, Dialysis and Transplantation.

[80]  H. Okamoto,et al.  A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. , 1995, Kidney international.

[81]  M. Jadoul,et al.  Hepatitis G virus infection in haemodialysed patients: epidemiology and clinical relevance. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[82]  G. Ippolito,et al.  Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: experience in an Italian region. The Latium Hepatitis Prevention Group. , 1991, Nephron.

[83]  H. Hayashi,et al.  Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. , 1995, Gastroenterology.

[84]  C. Apetrei,et al.  Nephrology Dialysis Transplantation Hepatitis Virus Infection in Haemodialysis Patients from Moldavia , 2022 .

[85]  D. de Zeeuw,et al.  Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. , 1985, Nephron.

[86]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States, 1993. , 1996, ASAIO journal.

[87]  P. Martín,et al.  Hepatitis e Virus in End-Stage Renal Disease , 1999, The International journal of artificial organs.

[88]  F. Locatelli,et al.  Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[89]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[90]  J. A. Al Wakeel,et al.  Hepatitis C in chronic renal failure patients. , 1992, American journal of nephrology.

[91]  M. Elisaf,et al.  Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit , 1998, Transfusion.

[92]  A. Zuckerman,et al.  Molecular epidemiology of hepatitis B virus mutants , 1999, Journal of medical virology.

[93]  F. Locatelli,et al.  Hepatitis G virus infection in chronic dialysis patients and kidney transplant recipients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[94]  D. Docci,et al.  Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. , 1992, Nephron.

[95]  A. Eddleston,et al.  Immune response to HBsAg and the spectrum of liver lesions in HBsAg-positive patients with chronic renal disease. , 1976, British medical journal.

[96]  M. Alter,et al.  National surveillance of hemodialysis associated diseases in the United States, 1990. , 1993, ASAIO journal.

[97]  S. Lee,et al.  Improved Detection of Anti‐HCV in Post‐Transfusion Hepatitis by a Third‐Generation ELISA , 1995, Vox sanguinis.

[98]  S. Kellerman,et al.  Preventing hepatitis B and hepatitis C virus infections in end‐stage renal disease patients: Back to basics , 1999, Hepatology.

[99]  T. Nishizawa,et al.  A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. , 1997, Biochemical and biophysical research communications.

[100]  W. Hop,et al.  Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma‐derived vaccine with and without pre‐S 2 antigen , 1990 .

[101]  H. Margolis,et al.  Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[102]  M. J. Cole,et al.  Quantitative Assessment of HCV Load in Chronic Hemodialysis Patients: A Cross-Sectional Survey , 1998, Nephron.

[103]  F. Locatelli,et al.  Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[104]  N. Sinelli,et al.  Hepatitis G Virus Infection in Haemodialysis and in Peritoneal Dialysis Patients , 1999, Nephron.

[105]  D. Marcelli,et al.  Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[106]  T. Mughal,et al.  Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[107]  Ülver Derici,et al.  Prevalence of Hepatitis E Virus Antibody in Hemodialysis Patients , 1998, Nephron.

[108]  H. Okamoto,et al.  Infection with GB virus C (GBV‐C) in patients with chronic liver disease or on maintenance hemodialysis in Indonesia , 1996, Journal of Medical Virology.

[109]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[110]  W. Szmuness,et al.  HEPATITIS B VACCINE: IMMUNE RESPONSES IN HAEMODIALYSIS PATIENTS , 1980, The Lancet.

[111]  H. Probst,et al.  Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[112]  C. Gibbs,et al.  Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. , 1999, Transplantation.

[113]  K. Masuko,et al.  GB virus C and hepatitis C virus infections in hemodialysis patients in eight Japanese centers. , 1997, Nephron.

[114]  M. Rothstein,et al.  Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. , 1979, Archives of internal medicine.

[115]  H. Alter.  New kit on the block: Evaluation of second‐generation assays for detection of antibody to the hepatitis C virus , 1992, Hepatology.

[116]  J. Hamilton,et al.  Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. , 1993, Vaccine.

[117]  K. Yamaguchi,et al.  Hepatitis C virus antibodies in haemodialysis patients , 1990, The Lancet.

[118]  M. Vallés,et al.  Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[119]  J. Patterson,et al.  Molecular mechanisms of action of ribavirin. , 1990, Reviews of infectious diseases.

[120]  D. Donati,et al.  Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. , 1988, Nephron.

[121]  S. Kashiwagi,et al.  Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. , 1991, Nephron.

[122]  M. Gonella,et al.  More about response to hepatitis B vaccine in hemodialysis patients. , 1988, Nephron.

[123]  J. Donoghue,et al.  Hepatitis E virus antibody prevalence , 1994, The Lancet.

[124]  S. Negroni,et al.  Results of a national epidemiological investigation on HCV infection among dialysis patients. (Survey by the Italian Branch of EDTNA/ERCA). , 1999, Journal of nephrology.

[125]  V. Carreño,et al.  Recombinant γ‐interferon as adjuvant to hepatitis B vaccine in hemodialysis patients , 1990 .

[126]  C. Leroux-Robert,et al.  Efficacy of intradermal injection of recombinant hepatitis B vaccine in dialysis patients. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[127]  A. Pizzuti,et al.  Hepatitis G virus infection in hemodialysis patients. , 1997, Kidney international.

[128]  S. Jacobson,et al.  Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden , 1998, Journal of medical virology.

[129]  E. Holmes,et al.  Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. , 1993, The Journal of general virology.

[130]  F. Chisari,et al.  Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. , 1985, Science.

[131]  T. Mettang,et al.  Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. , 1996, Nephron.

[132]  H. Varmus,et al.  The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.

[133]  M. Alter,et al.  National surveillance of dialysis-associated hepatitis and other diseases. 1976 and 1980 , 1983 .

[134]  K. Masuko,et al.  Infection with hepatitis GB virus C in patients on maintenance hemodialysis. , 1996, New England Journal of Medicine.

[135]  S. Laperche,et al.  Prevalence of present and past hepatitis G virus infection in a French haemodialysis centre. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[136]  J. Esteban,et al.  Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. , 1990, The New England journal of medicine.

[137]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States, 1995. , 1998, ASAIO journal.

[138]  M. Alter,et al.  Nosocomial transmission of delta hepatitis. , 1986, Annals of internal medicine.

[139]  M. Stojanovic,et al.  Prevention of Nosocomial Transmission of Hepatitis C Infection in a Hemodialysis Unit. A Prospective Study , 2000, The International journal of artificial organs.

[140]  T. Therneau,et al.  TT‐virus infection in north american blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis , 1998, Hepatology.

[141]  L. Tobler,et al.  Impact of specimen handling and storage on detection of hepatitis C virus RNA , 1992, Transfusion.

[142]  M. Ishigami,et al.  TT virus infection in hemodialysis patients , 1999, American Journal of Gastroenterology.

[143]  E. Tanaka,et al.  Clinical significance of hepatitis G virus infection in patients on long‐term haemodialysis , 1997, Journal of gastroenterology and hepatology.

[144]  M. Alter,et al.  National surveillance of dialysis-associated diseases in the United States, 1989. , 1991, ASAIO transactions.

[145]  F. Carnot,et al.  Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. , 1996, Transplantation.

[146]  J. Montoliu,et al.  Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[147]  Y. Liaw,et al.  High incidence of hepatitis C virus infection in hemodialysis patients in Taiwan. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[148]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States, 1991. , 1993, ASAIO journal.

[149]  W. V. van Dorp,et al.  Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[150]  A. Walker,et al.  Hepatitis B immunization in UK renal units: failure to put policy into practice. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[151]  N. Bianco,et al.  Risk factors for dialysis-associated hepatitis C in Venezuela. , 1992, Kidney international.

[152]  N. Waite,et al.  Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. , 1995, Journal of the American Society of Nephrology : JASN.

[153]  P. Brissot,et al.  Uremia and the liver. II. Drugs and the liver in the uremic patient. , 1981, Nephron.

[154]  F. Locatelli,et al.  Incidence of seroconversion for hepatitis C virus in chronic haemodialysis patients: a prospective study. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[155]  K. Bolla,et al.  THYMOPENTIN AS ADJUVANT IN NON-RESPONDERS OR HYPORESPONDERS TO HEPATITIS B VACCINATION , 1983, The Lancet.

[156]  L. Grillner,et al.  Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing. , 1995, The Journal of hospital infection.

[157]  P. Parfrey,et al.  HEPATITIS B DISEASE IN DIALYSIS AND TRANSPLANT PATIENTS FURTHER EPIDEMIOLOGIC AND SEROLOGIC STUDIES , 1987, Transplantation.

[158]  M. Buti,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. , 1992, American journal of nephrology.

[159]  D. Ouzan,et al.  High prevalence of hepatitis E virus antibody in haemodialysis patients , 1994, The Lancet.

[160]  M. Urdea,et al.  Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA , 1995, Journal of viral hepatitis.

[161]  F. Fabrizi,et al.  Epidemiology and Natural History of Hepatitis G Virus Infection in Chronic Hemodialysis Patients , 1999, American Journal of Nephrology.

[162]  C. Basile,et al.  Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[163]  M. Houghton,et al.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay , 1991, The Lancet.

[164]  P. Simmonds,et al.  Early acquisition of TT virus (TTV) in an area endemic for TTV infection. , 1999, The Journal of infectious diseases.

[165]  V. Carreño,et al.  Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule? , 1985, Clinical nephrology.

[166]  T. Hutchinson,et al.  THE CLINICAL AND PATHOLOGICAL COURSE OF HEPATITIS B LIVER DISEASE IN RENAL TRANSPLANT RECIPIENTS , 1984, Transplantation.